Agoraphobia Companies

Latest Agoraphobia Companies Update

• 
  Nov 2023: Breyanzi (lisocabtagene maraleucel), manufactured by Bristol Myers Squibb (BMS), has been given priority review by the US Food and Drug Administration (FDA) to treat patients with small lymphocytic lymphoma (SLL) or chronic lymphocytic leukemia (CLL) that has relapsed or is refractory. The therapy's Prescription Drug User Fee Act (PDUFA) goal date is March 14, 2024. To expand the use of Breyanzi for the treatment of patients with CLL and SLL who have already received a B-cell lymphoma 2 inhibitor (BCL2i) and a Bruton tyrosine kinase inhibitor (BTKi), BMS submitted a supplemental biologics license application (sBLA) to the FDA.

• Regulators in the US and the UK approved Eli Lilly's Zepbound weight-loss medication, opening the door for a potent new competitor to Novo Nordisk's Wegovy in the fight against the nation's alarmingly high obesity rates. At the end of the decade, the two medications are expected to compete in an international market valued at $100 billion. They are the most successful weight-loss medicines that have been approved yet. Due to Novo's drugs, patients have lost a significant amount of weight, which has changed the market for companies that sell sugar-filled foods and drinks, healthcare providers that sell products to treat obesity-related conditions like diabetes and sleep apnea, and manufacturers of equipment used in bariatric surgeries. Additionally, drug manufacturers have come under fire for the exorbitant price of the medicines that make them unaffordable for many who suffer from obesity.

• Eli Lilly & Co.


• Bristol-Myers Squibb


• AstraZeneca


• Pfizer inc


• GlaxoSmithKline plc


• Johnson & Johnson


• Sandoz Inc.


• Apotex Corp.


• Mylan Pharmaceuticals